• PCV75 DERIVING COST INPUT VALUES FOR USE IN A MARKOV MODEL FOR EXPLORING THE CLINICAL CONSEQUENCES OF RIMONABANT IN ADDITION TO DIET AND EXERCISE IN OVERWEIGHT OR OBESE SUBJECTS

    Nov 1, 2006, 00:00

  • PND2 ESTIMATING THE BUDGET IMPACT OF LEVETIRACETAM AS ADJUNCTIVE THERAPY IN CHILDREN WITH REFRACTORY PARTIAL ONSET SEIZURE IN THE UK

    Nov 1, 2006, 00:00

  • PCN67 PREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING WITH 5HT3 RECEPTOR ANTAGONISTS AND HEALTH RELATED QOL

    Nov 1, 2006, 00:00

  • PGI13 ECONOMIC EVALUATION OF THE ARTIFICIAL LIVER SUPPORT SYSTEM MARS IN PATIENTS WITH ACUTE-ONCHRONIC LIVER FAILURE-FINAL RESULTS OF A CLINICAL COHORT TRIAL

    Nov 1, 2006, 00:00

  • PMH14 PHARMACOECONOMIC POSITIONING OF SERTINDOLE AMONG ANTIPSYCHOTICS IN THE MANAGEMENT OF SCHIZOPHRENIA- THE HUNGARIAN EXPERIENCE

    Nov 1, 2006, 00:00

  • POS5 AN ECONOMIC EVALUATION OF ZOLEDRONIC ACID TREATMENT IN PAGET'S DISEASE OF BONE IN THE HUNGARIAN HEALTH CARE SETTING

    Nov 1, 2006, 00:00

  • PRS9 CLINICAL PRACTICE VS GOLD RECOMMENDATIONS IN THE MANAGEMENT OF COPD PATIENTS- AN ECONOMIC ANALYSIS OF THE LACK OF ADHERENCE TO GUIDELINES

    Nov 1, 2006, 00:00

  • PCV65 ECONOMIC APPRAISAL OF THE ANGIOPLASTY PROCEDURES PERFORMED IN 2004 IN A HIGH-VOLUME DIAGNOSTIC AND SURGICAL CARDIOLOGY UNIT

    Nov 1, 2006, 00:00

  • PCV59 LIPID TESTING AMONG PATIENTS RECEIVING FIRST-EVER STATIN THERAPY IN UK GENERAL PRACTICES

    Nov 1, 2006, 00:00

  • PDB5 PREVENTION WITH PICOTAMIDE AND ASPIRIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND PERIPHERAL ARTERIAL DISEASE-A PHARMACOECONOMIC EVALUATION

    Nov 1, 2006, 00:00

  • PDB16 SELF MONITORING OF BLOOD GLUCOSE IN PATIENTS WITH TYPE 2 DIABETES- COST UTILITY ANALYSIS IN A FRENCH GOVENMENT PAYER SETTING

    Nov 1, 2006, 00:00

  • PIN13 ECONOMIC EVALUATION OF EARLY MONOTHERAPY WITH INTERFERON VERSUS DELAYED COMBINATION THERAPY WITH INTERFERON AND RIBAVIRIN IN PATIENTS WITH ACUTE HEPATITIS C

    Nov 1, 2006, 00:00

  • PIH5 COST-EFFECTIVENESS OF DUTASTERIDE IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH)

    Nov 1, 2006, 00:00

  • PIN19 COST-EFFECTIVENESS OF MASS VACCINATION WITH A ROTAVIRUS VACCINE IN THE NETHERLANDS

    Nov 1, 2006, 00:00

  • POB10 RIMONABANT IMPROVES HEALTH-RELATED QUALITY OF LIFE IN OVERWEIGHT/OBESE PATIENTS WITH TYPE 2 DIABETES- RIO-DIABETES STUDY

    Nov 1, 2006, 00:00

  • PMH5 A 3-MONTH ASSESSMENT OF TREATMENT PRESCRIBED TO PATIENTS WITH ADHD AND ITS IMPACT ON CLINICAL SEVERITY AND QOL OUTCOMES ACROSS 10 EUROPEAN COUNTRIES. RESULTS FROM ATTENTION DEFICIT/ HYPERACTIVITY DISODER OBSERVATIONAL RESEARCH IN EUROP ...

    Nov 1, 2006, 00:00

  • PHP39 EVALUATION OF SCIENTIFIC QUALITY OF POSTMARKETING SURVEILLANCE STUDIES IN GERMANY

    Nov 1, 2006, 00:00

  • PIH24 PREFERENCES IN ITALIAN BPH PATIENTS

    Nov 1, 2006, 00:00

  • PMH39 USE OF VERBALLY ADMINISTERED AND VERBALLY ORIENTING SCALES TO IMPROVE DATA COLLECTION

    Nov 1, 2006, 00:00

  • ES2 DIRECT MEDICAL COSTS OF SOLID ORGAN TRANSPLANT IN BRITISH COLUMBIA, CANADA

    Nov 1, 2006, 00:00

  • CV3 COST-EFFECTIVENESSS OF INTENSIVE STATIN THERAPY COMPARED TO MODERATE STATIN THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME- ANALYSIS FROM CANADA, GERMANY AND THE UK

    Nov 1, 2006, 00:00

  • PHP4 ASSESSING THERAPEUTIC IMPROVEMENT IN CANADA AND FRANCE- A COMPARISON OF PMPRB AND ASMR CLASSIFICATIONS

    Nov 1, 2006, 00:00

  • PEY7 MODELLING THE HEALTH ECONOMIC IMPACT OF OLOPATADINE COMPARED TO BRANDED AND GENERIC SODIUM CROMOGLYCATE IN THE TREATMENT OF SEASONAL ALLERGIC CONJUNCTIVITIS IN THE UK

    Nov 1, 2006, 00:00

  • PUK2 LINKING CNI REGIMEN ADHERENCE TO HOSPITAL DAYS AND HEALTH CARE COSTS

    Nov 1, 2006, 00:00

  • PMC18 USING DISTANCE LEARNING TO UNDERSTAND DISCRETE EVENT SIMULATION

    Nov 1, 2006, 00:00

  • PMH23 PREDICTING VIOLENT OFFENDING AMONG MENTALLY ILL IN A MULTINATIONAL SETTING–NAIVE BAYESIAN FUSION AND MODEL MERGING WITH P-COURSE

    Nov 1, 2006, 00:00

  • HP4 SUMMARIZING POPULATION HEALTH USING EQ-5D

    Nov 1, 2006, 00:00

  • PDB26 COST-EFFECTIVENESS OF ROSIGLITAZONE FOR TREATMENT OF TYPE 2 DIABETES IN PORTUGAL USING DIFFERENT METHODS TO MODEL CLINICAL EFFECTS

    Nov 1, 2006, 00:00

  • PAA1 CLINICAL EFFECTIVENESS OF ADJUSTABLE DOSING SINGLE INHALER BUDESONIDE/FORMOTEROL FOR ASTHMA AND BUDGET IMPACT ANALYSIS

    Nov 1, 2006, 00:00

  • PCV30 COST-EFFECTIVENESS OF ROSUVASTATIN FOR CARDIOVASCULAR PREVENTION IN HIGH-RISK POPULATIONS IN SWEDEN

    Nov 1, 2006, 00:00

  • PCN56 OUTCOME VALIDATION OF A SUCCINCT HPV INFECTION MODEL FOR FRANCE

    Nov 1, 2006, 00:00

  • ES3 PROCESS OPTIMIZATION IN A 10-BED INTENSIVE CARE UNIT (ICU) IN GERMANY- IMPACT ON CASE-RELATED TREATMENT COSTS

    Nov 1, 2006, 00:00

  • PCV90 DEVELOPMENT OF A NEW MEASURE FOR ASSESSING HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ATRIAL FIBRILLATION-“AF-QOL”

    Nov 1, 2006, 00:00

  • PDB2 AN EVALUATION OF DIABETES CONTROL AND REPORTS OF HYPOGLYCAEMIA IN UK GENERAL PRACTICE FOLLOWING INITIATION OF INSULIN GLARGINE VERSUS INSULIN DETEMIR USING OBSERVATIONAL, REAL-LIFE DATA

    Nov 1, 2006, 00:00

  • PCV35 ESTIMATING LIFETIME COSTS AND LIFE EXPECTANCY ASSOCIATED WITH CARDIOVASCULAR DISEASE IN A SWISS POPULATION WITH AND WITHOUT METABOLIC SYNDROME

    Nov 1, 2006, 00:00

  • Too Much Ado about Propensity Score Models? Comparing Methods of Propensity Score Matching

    Nov 1, 2006, 00:00

  • PDB28 INADEQUATE GLYCEMIC CONTROL- IS IT RELATED WITH MORE COMORBIDITIES AND MORE RESOURCE UTILIZATION?

    Nov 1, 2006, 00:00

  • PUK26 LINGUISTIC VALIDATION OF THE OVERACTIVE BLADDER SATISFACTION QUESTIONNAIRE (OAB-S) IN 13 LANGUAGES

    Nov 1, 2006, 00:00

  • PDB11 LONG-TERM COST-EFFECTIVENESS ANALYSIS OF REPAGLINIDE VERSUS NATEGLINIDE IN COMBINATION WITH METFORMIN IN TYPE 2 DIABETES PATIENTS FAILING MONOTHERAPY IN THE SWEDISH SETTING

    Nov 1, 2006, 00:00

  • PMH8 BUDGET IMPACT MODEL FOR DETERMINING THE COSTS OF INTRODUCING ZIPRASIDONE FOR THE MANAGEMENT OF ACUTE BIPOLAR MANIA IN SPAIN

    Nov 1, 2006, 00:00

  • PDB18 COST-EFFECTIVENESS OF ACARBOSE IN PATIENTS WITH TYPE-2 DIABETES IN THREE COUNTRIES

    Nov 1, 2006, 00:00

  • PRS13 USING PATIENT DESCRIPTORS TO DEVELOP A PRO MEASUREMENT STRATEGY FOR CLINICAL TRIALS- EVALUATING THE COPD PATIENT'S EXPERIENCE OF DYSPNEA

    Nov 1, 2006, 00:00

  • PHP8 ANTIBIOTIC UTILIZATION IN NIS REGION OF SERBIA AND MONTENEGRO

    Nov 1, 2006, 00:00

  • PCV82 VALIDATION OF A MODEL TO PREDICT LIFETIME CLINICAL AND ECONOMIC BENEFIT OF RAISING HDL-C IN STATINTREATED PATIENTS WITH PERSISTENTLY LOW HDL-C

    Nov 1, 2006, 00:00

  • Estimating the Cost-Effectiveness of Quality-Improving Interventions in Oral Anticoagulation Management within General Practice

    Nov 1, 2006, 00:00

  • PCN8 RISE OF HEALTH RESOURCE UTILIZATION AND COSTS FOR SEQUENTIAL DOCETAXEL IN NODE-POSITIVE PRIMARY BREAST CANCER IN GERMAN HOSPITALS

    Nov 1, 2006, 00:00

  • PCN25 TREATMENT OF ACTINIC KERATOSIS (AK) AND BASAL CELL CARCINOMA (BCC) WITH METVIX® (MAL-PDT) IN REAL LIFE PRACTICE- A COST OF ILLNESS AND MODEL VALIDATION STUDY

    Nov 1, 2006, 00:00

  • PPN4 ECONOMIC EVALUATION COMPARING BMP-2 (INDUCTOSTM) VERSUS CURRENT TREATMENT IN CHRONIC LOWER BACK PAIN IN THE SPANISH SETTING

    Nov 1, 2006, 00:00

  • PCN66 ADHERENCE IN CANCER PATIENTS RECEIVING ORAL CAPECITABINE

    Nov 1, 2006, 00:00

  • PDB13 THE RELATIVE COST EFFECTIVENESS OF INSULIN GLARGINE VERSUS NPH INSULIN IN THE UK IN PEOPLE WITH TYPE 2 DIABETES

    Nov 1, 2006, 00:00

  • MC3 USING SIMULATIONS TO EXPLORE THE INFLUENCE OF COMPETING RISK ON TREATMENT-EFFECT

    Nov 1, 2006, 00:00

  • PMH29 ACUTE HOSPITALIZATION IN THE ELDERLY-RELATIONSHIP WITH PSYCHIATRIC MORBIDITY AND SOCIAL EQUITY IN HEALTH CARE ACESS IN SINGAPORE

    Nov 1, 2006, 00:00

  • POS6 ECONOMIC ANALYSIS- IBANDRONATE (BONVIVA®) IV INJECTION FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS (PMO) IN THE UK

    Nov 1, 2006, 00:00

  • PCV49 COST-UTILITY ANALYSIS USING A MARKOV MODEL TO COMPARE PRESCRIPTION STATINS VERSUS POTENTIAL OVER THE COUNTER STATINS IN USA

    Nov 1, 2006, 00:00

  • PCN1 THE EPIDEMIOLOGIC, HEALTH-RELATED QUALITY OF LIFE, AND ECONOMIC BURDEN OF GASTROINTESTINAL STROMAL TUMORS

    Nov 1, 2006, 00:00

  • PCN49 FACTORS INFLUENCING INEQUITABLE ACCESS TO RADIATION THERAPY- THE CASE STUDY OF CANCER PATIENTS IN THAILAND

    Nov 1, 2006, 00:00

  • PUK10 A COMPARATIVE STUDY OF THE ECONOMIC BURDEN OF OVERACTIVE BLADDER AND URINARY URGE INCONTINENCE ACROSS 6 WESTERN COUNTRIES

    Nov 1, 2006, 00:00

  • PDB48 MANAGEMENT AND TREATMENT ADHERENCE IN TYPE 2 DIABETIC PATIENTS IN SPAIN

    Nov 1, 2006, 00:00

  • PAA10 HEALTH PLAN STRUCTURE AND EXPENDITURES FOR ASTHMA CARE

    Nov 1, 2006, 00:00

  • PMC1 SIMULATION MODELING OF CARDIOVASCULAR DISEASE- IS APPLYING AVERAGE LIFE EXPECTANCY TO ALL SURVIVORS DETAILED ENOUGH?

    Nov 1, 2006, 00:00

  • PCN55 LONG TERM CLINICAL EFFECT OF AN HPV-VACCINE FOR THE PREVENTION OF CERVICAL CANCER IN FRANCE IN RELATION TO AGE OF VACCINATION- RESULTS FROM A MARKOV MODEL

    Nov 1, 2006, 00:00

  • CN3 PHARMACOECONOMIC (PE) ANALYSIS OF THE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC) IN THE NETHERLANDS DEMONSTRATES THAT ERLOTINIB DOMINATES DOCETAXEL AND IS COST-EFFECTIVE OVER BEST SUPPORTIVE CARE (BSC) WITHOUT NEED FOR PATIENT STRA ...

    Nov 1, 2006, 00:00

  • PDB15 SELF MONITORING OF BLOOD GLUCOSE IN PATIENTS WITH TYPE 2 DIABETES- COST UTILITY ANALYSIS IN AN ITALIAN SETTING

    Nov 1, 2006, 00:00

  • PCN17 COST EFFECTIVENESS OF PRIMARY PROPHYLAXIS WITH PEGFILGRASTIM OR FILGRASTIM IN THE MEDICAL TREATMENT OF BREAST CANCER IN ITALY

    Nov 1, 2006, 00:00

  • PHP38 HEALTH TECHNOLOGY ASSESSMENT IN HUNGARY

    Nov 1, 2006, 00:00

  • PHP14 STAKEHOLDERS' PERSPECTIVES ON IMPROVING ACCESS TO PRIMARY CARE

    Nov 1, 2006, 00:00

  • PCN69 HEALTH UTILITIES IN THE UK FOR SECOND LINE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) FOLLOWING PRIOR CHEMOTHERAPY

    Nov 1, 2006, 00:00

  • PHP5 THE PHARMACEUTICAL INDUSTRY PERSPECTIVE ON PHARMACOECONOMICS IN SAUDI ARABIA

    Nov 1, 2006, 00:00

  • PCN29 ECONOMIC ADVANTAGES AND TIMESAVING OF USING OXALIPLATIN CONCENTRATED SOLUTION VERSUS OXALIPLATIN LYOPHILISED POWDER FOR INFUSION

    Nov 1, 2006, 00:00

  • PND14 TREATMENT OF NEUROPATHIC PAIN IN MULTIPLE SCLEROSIS- A POPULATION BASED WILLINGNESS-TO-PAY ANALYSIS

    Nov 1, 2006, 00:00

  • DB4 SELF MONITORING OF BLOOD GLUCOSE IN PATIENTS WITH TYPE 2 DIABETES- COST UTILITY ANALYSIS IN A UNITED STATES THIRD-PARTY PAYER SETTING

    Nov 1, 2006, 00:00

  • POS13 THE ESTIMATION OF COST–EFFECTIVENESS THRESHOLDS PRIOR TO THE START OF LARGE CLINICAL STUDIES

    Nov 1, 2006, 00:00

  • PHM2 INPATIENT RESOURCE USE AND COSTS OF TRAUMA IN PATIENTS WITH VS WITHOUT BLOOD TRANSFUSION- EVIDENCE FROM THE HEALTH CARE COST AND UTILIZATION PROJECT DATABASE

    Nov 1, 2006, 00:00

  • PMC12 REVIEW ON THE IMPACT OF DOSE FREQUENCY ON COMPLIANCE AND HEALTH OUTCOMES

    Nov 1, 2006, 00:00

  • PCV19 DISCONTINUED USE OF MYCOPHENOLATE MOFETIL AND GRAFT LOSS IN HEART TRANSPLANT RECIPIENTS

    Nov 1, 2006, 00:00

  • PIH21 INFLUENCE OF CONCOMITANT DISEASES ON THE CLINICAL RESPONSE TO TREATMENT FOR ERECTILE DYSFUNCTION

    Nov 1, 2006, 00:00

  • PCN27 COST-EFFECTIVENESS AND COST-UTILITY OF FENTANYL TTS (DUROGESIC® 25, 50) VS. SR/IR ORAL MORPHINES IN THE MANAGEMENT OF CHRONIC CANCER PAIN

    Nov 1, 2006, 00:00

  • PMH31 PREDICTORS FOR REHOSPITALIZATION IN PATIENTS WITH SCHIZOPHRENIA

    Nov 1, 2006, 00:00

  • CV1 COST-EFFECTIVENESS OF EPTIFIBATIDE IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION IN GERMANY

    Nov 1, 2006, 00:00

  • PRS12 EXPECTED VALUE OF PERFECT INFORMATION- A PRACTICAL EXAMPLE OF REDUCING DECISION UNCERTAINTY BY CONDUCTING ADDITIONAL RESEARCH

    Nov 1, 2006, 00:00

  • PCN6 PRIMARY PROPHYLAXIS WITH PEGFILGRASTIM IS COSTSAVING COMPARED WITH FILGRASTIM FOR BREAST CANCER IN SPAIN

    Nov 1, 2006, 00:00

  • PIN8 COST-EFFECTIVENESS OF INTERVENTIONS ENSURING BLOOD TRANSFUSION SAFETY IN AFRICA

    Nov 1, 2006, 00:00

  • PMH34 IMPROVEMENTS IN ILLNESS SEVERITY AND FUNCTIONING IN SCHIZOPHRENIC PATIENTS SWITCHED TO RISPERIDONE LONG-ACTING INJECTION (RLAI)

    Nov 1, 2006, 00:00

  • SZ2 TREATMENT PERSISTENCE WITH DIFFERENT ANTIPSYCHOTICS IN PATIENTS WITH SCHIZOPHRENIA

    Nov 1, 2006, 00:00

  • PSU4 VENTRAL, UMBILICAL, AND INGUINAL HERNIA- REVIEW OF THE CURRENT LITERATURE

    Nov 1, 2006, 00:00

  • PUK27 RISK OF LEAKAGES IN DAILY ACTIVITIES, RE-WORKING THE CONCEPTUAL FRAMEWORK

    Nov 1, 2006, 00:00

  • PSK7 CONVERGENT VALIDITY AND SENSITIVITY TO CHANGE OF GENERIC AND DISEASE-SPECIFIC INSTRUMENTS USED IN CHILDREN WITH ATOPIC DERMATITIS

    Nov 1, 2006, 00:00

  • PIH23 ERECTILE DYSFUNCTION IN SPAIN- CLINICAL RESPONSE TO TREATMENTS

    Nov 1, 2006, 00:00

  • PCV38 COST MINIMIZATION ANALYSIS OF BIVALIRUDIN VERSUS HEPARIN PLUS PLANNED ABXICIMAB IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION

    Nov 1, 2006, 00:00

  • PUK18 A MULTICENTRE STUDY OF RENAL TRANSPLANT PATIENTS USING THE SF-36 AND THE END STAGE RENAL DISEASE SYMPTOM CHECK-LIST (ESRD-SCL)

    Nov 1, 2006, 00:00

  • PCV16 MAIN CARDIOVASCULAR RISK FACTORS- ASSOCIATION AND CONTROL IN A PRIMARY HEALTH CARE SETTING

    Nov 1, 2006, 00:00

  • PDB1 BETTER HBA1C CONTROL WITH BOT VERSUS CT AVOIDS LONG-TERM MICRO-VASCULAR COMPLICATIONS IN PATIENTS WITH TYPE-2-DIABETES- MODEL SIMULATIONS WITH THE DMM

    Nov 1, 2006, 00:00

  • PCV6 REACHING SIGN CHOLESTEROL TARGETS AND BEYOND- RETROSPECTIVE AUDIT OF TARGETS ACHIEVED THROUGH USE OF ROSUVASTATIN IN A SCOTTISH GENERAL PRACTICE

    Nov 1, 2006, 00:00

  • PAR7 DIFFUSION OF HEALTH TECHNOLOGIES IN DENMARK- LAGGARDS OR EARLY ADOPTERS?-FOUR CASE-STUDIES REGARDING DRIVERS AND BARRIERS

    Nov 1, 2006, 00:00

  • PUK3 BUDGET IMPACT ANALYSIS OF INCLUDING RENAL REPLACEMENT THERAPY IN THE BENEFIT PACKAGE OF UNIVERSAL COVERAGE IN THAILAND

    Nov 1, 2006, 00:00

  • PIH8 PROPORTION OF HERPES ZOSTER (HZ) PATIENTS DEVELOPING POST-HERPETIC NEURALGIA (PHN) AND ITS MANAGEMENT IN THE UK

    Nov 1, 2006, 00:00

  • GI3 COST-UTILITY ANALYSIS IN A UK SETTING OF VASOACTIVE DRUG TREATMENTS IN ACUTE BLEEDING OESOPHAGEAL VARICES IN CIRRHOTIC PATIENTS-A DISCRETE EVENT SIMULATION MODEL

    Nov 1, 2006, 00:00

  • PCN34 EFFECT OF METASTASIS LOCALIZATION ON SYMPTOMS AND ASSISTANCE COSTS IN ADVANCED NSCLC PATIENTS. FURTHER EVIDENCE FROM THE HABIT STUDY

    Nov 1, 2006, 00:00

  • PDB10 LONG-TERM CLINICAL AND ECONOMIC OUTCOMES FOR PATIENTS WITH TYPE 1 DIABETES TREATED WITH INSULIN ASPART VERSUS HUMAN SOLUBLE INSULIN IN SWEDEN

    Nov 1, 2006, 00:00

  • PGI18 DISCRIMINANT VALIDITY OF THE WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT QUESTIONNAIRE IN PATIENTS WITH CROHN'S DISEASE

    Nov 1, 2006, 00:00

  • PCV47 DIRECT MEDICAL COSTS FOR TREATMENT OF MILD TO MODERATE HYPERTENSION IN PATIENTS WITH TYPE II DIABETES

    Nov 1, 2006, 00:00

  • PHP31 THE ECONOMIC EVALUATION OF HOME PHARMACIES IN HEALTH AREA

    Nov 1, 2006, 00:00

  • PCV83 COMPLIANCE PATTERN OF PHARMACOLOGICAL REGIMENS IN HYPERTENSIVES AND/OR DYSLIPIDEMIC PATIENTS IN AMBULATORY CARE IN A SPANISH POPULATION

    Nov 1, 2006, 00:00

  • PMC16 PROPOSED CHANGES TO PHYSICIAN FEE SCHEDULE- 2007 PRACTICE EXPENSE CONCEPTUAL METHODOLOGY

    Nov 1, 2006, 00:00

  • PMH26 RESOURCE USE AMONG PATIENTS WITH SCHIZOPHRENIA IN 5 EUROPEAN COUNTRIES

    Nov 1, 2006, 00:00

  • PCN5 HEXVIX FLUORESCENCE CYSTOSCOPY FOR SUPERFICIAL BLADDER CANCER DIAGNOSIS- ANALYSIS OF BUDGET IMPACT ON THE SWEDISH HEALTH SERVICE

    Nov 1, 2006, 00:00

  • PUK19 OPEN MULTICENTER STUDY OF HEALTH RE LATED QUALITY OF LIFE BEFORE AND AFTER SOLID ORGAN TRANSPLANTATION (KIDNEY, LIVER, HEART AND LUNG)

    Nov 1, 2006, 00:00

  • PCN53 AGE-GROUP SPECIFIC COVERAGE OF THE HUNGARIAN ORGANIZED NATIONWIDE CERVICAL CANCER SCREENING PROGRAMME

    Nov 1, 2006, 00:00

  • PUK13 TRENDS IN MEDICATION PRESCRIPTION FOR ANEMIA MANAGEMENT OF CHRONIC KIDNEY DISEASE IN A NATIONALLY REPRESENTATIVE SAMPLE OF OUTPATIENT SETTINGS IN THE UNITED STATES

    Nov 1, 2006, 00:00

  • PRS14 PERSISTENCE WITH TIOTROPIUM- A COMPARISON WITH ESTABLISHED MEDICATIONS FOR COPD

    Nov 1, 2006, 00:00

  • PHP37 GENERIC COMPETITION- EFFECT ON PRICES AND SUBSTITUTION EFFECTS

    Nov 1, 2006, 00:00

  • Value in Health

    Nov 1, 2006, 00:00

  • PRS1 PREVALENCE AND TREATMENT OF COPD IN GERMANY

    Nov 1, 2006, 00:00

  • PMH47 MEASURING RELAPSE AFTER ADOLESCENT SUBSTANCE ABUSE TREATMENT- A PROPORTIONAL HAZARD APPROACH

    Nov 1, 2006, 00:00

  • PCV20 FINANCIAL IMPACT OF EPLERENONE USE IN A SPANISH REFERENCE HOSPITAL

    Nov 1, 2006, 00:00

  • PMH15 COST-EFFECTIVENESS OF AMISULPRID COMPARED TO RISPERIDONE AND OLANZAPINE IN THE TREATMENT OF SCHIZOPHRENIA IN POLAND

    Nov 1, 2006, 00:00

  • PIN9 COST-EFFECTIVENESS ANALYSIS OF COMBINED THERAPY WITH PEGINTERFERON ALFA-2A (40KD) (PEGASYS) AND RIBAVIRIN (COPEGUS) IN PATIENTS WITH CHRONIC C HEPATITIS (CHC) AND HUMAN IMMUNODEFICIENCY VIRUS (HIV) CO-INFECTION

    Nov 1, 2006, 00:00

  • PEY25 HEALTH-RELATED QUALITY-OF-LIFE AND UTILITY IN DUTCH GLAUCOMA PATIENTS

    Nov 1, 2006, 00:00

  • PHM10 QUALITY OF LIFE IN PATIENTS WITH BETA THALASSEMIA MAJOR- RESULTS FROM THE ITHACA STUDY

    Nov 1, 2006, 00:00

  • PAA11 COST-EFFECTIVENESS ANALYSIS FOR THE ASSESSMENT OF PREVENTIVE SCHEMES BASED ON GENETIC SCREENING

    Nov 1, 2006, 00:00

  • PND3 COST-EFFECTIVENESS ANALYSIS OF ADD-ON THERAPY IN PARTIAL REFRACTORY EPILEPSY IN MEXICO

    Nov 1, 2006, 00:00

  • PUK28 VALIDATION OF THE PELVIC ORGAN PROLAPSE/URINARY INCONTINENCE SEXUAL FUNCTION QUESTIONNAIRE IN ITALIAN WOMEN. THE GYNAEFLOW STUDY

    Nov 1, 2006, 00:00

  • POB5 A MODELLED COST-EFFECTIVENESS EVALUATION OF SIBUTRAMINE THERAPY IN A HIGH RISK OBESE POPULATION

    Nov 1, 2006, 00:00

  • PCV80 DERIVING UTITLITY VALUES FOR USE IN A MARKOV MODEL FOR EXPLORING THE CLINICAL CONSEQUENCES OF RIMONABANT IN ADDITION TO DIET AND EXERCISE IN OVERWEIGHT OR OBESE SUBJECTS

    Nov 1, 2006, 00:00

  • PCN4 A COMPARATIVE BUDGET IMPACT (BI) ANALYSIS OF ARANESP® (DARBEPOETIN ALFA) 500 mGQ3W VERSUS OTHER ERYTHROPOIESIS STIMULATING PROTEINS (ESP) IN CHEMOTHERAPY-INDUCED ANEMIA (CIA) IN SPAIN

    Nov 1, 2006, 00:00

  • PCV74 COST-EFFECTIVENESS ANALYSIS IN CORONARY ARTERY DISEASE DIAGNOSIS- CHOOSING BETWEEN LABORATORY MARKERS

    Nov 1, 2006, 00:00

  • PCV86 CHARACTERIZATION OF HYPERTENSIVE PATIENTS WHO MIGHT BENEFIT FROM A COMBINATION OF TWO DRUGS IN ONE PILL FOR REDUCTION OF CARDIOVASCULAR RISK

    Nov 1, 2006, 00:00

  • PIH19 ESTIMATING UTILITY IN ROTAVIRUS GASTROENTERITIS IN CHILDREN UNDER FIVE IN THE UK

    Nov 1, 2006, 00:00

  • PCN10 INCREMENTAL COST-EFFECTIVENESS RATIO OF DARBEPOETIN ALFA (ARANESP®) IN THE TREATMENT OF CHEMOTHERAPY-INDUCED ANEMIA IN LUNG CANCER PATIENTS

    Nov 1, 2006, 00:00

  • PDB7 THE RELATIVE COST EFFECTIVENESS OF INSULIN GLARGINE VERSUS NPH INSULIN IN THE UK IN PEOPLE WITH TYPE 1 DIABETES

    Nov 1, 2006, 00:00

  • PCV81 VALIDATION OF THE MODE OF ADMINISTRATION OF THE MEDICATION COMPLIANCE QUESTIONNAIRE

    Nov 1, 2006, 00:00

  • PEY20 MEASURING CURRENT USE OF OCULAR HYPOTENSIVE THERAPIES- ACCOUNTING FOR RESTART RATES

    Nov 1, 2006, 00:00

  • PIH18 DIMENSIONS OF HRQOL AND SATISFACTION WITH LIFE IMPROVE IN ED PATIENTS SWITCHING FROM OTHER ORAL ED MEDICATION TO TADALAFIL

    Nov 1, 2006, 00:00

  • PIN7 THE COST-EFFECTIVENESS OF ENTECAVIR IN THE LONGTERM TREATMENT OF NUCLEOSIDE-NAÏVE AND LAMIVUDINE-REFRACTORY CHRONIC HEPATITIS B PATIENTS IN SWEDEN

    Nov 1, 2006, 00:00

  • PMH2 PREVALENCE OF METABOLIC SYNDROME IN PATIENTS WITH BIPOLAR DISORDER-A CROSS-SECTIONAL ASSESSMENT OF A HEALTH MANAGEMENT ORGANIZATION IN SPAIN

    Nov 1, 2006, 00:00

  • PRS15 IMPROVING THE PERSISTENCE OF PATIENTS UNDERGOING SUBLINGUAL IMMUNOTHERAPY- SCORING AND VALIDATION OF A PATIENT-MANAGEMENT TOOL

    Nov 1, 2006, 00:00

  • PCV29 COST-EFFECTIVENESS ANALYSIS OF ROSUVASTATIN IN TREATING PATIENTS TO LDL-C ATP III GOALS. A MEXICAN PERSPECTIVE OF THE STELLAR TRIAL

    Nov 1, 2006, 00:00

  • PND10 A FUNCTIONAL ANALYSIS OF THE RELATIONSHIP BETWEEN AGE AND MIGRAINE IN THE UNITED STATES OF AMERICA

    Nov 1, 2006, 00:00

  • IH1 PATIENTS' WILLINGNESS TO PAY FOR DIFFERENT CHARACTERISTICS OF THE ATOPIC DERMATITIS TREATMENT

    Nov 1, 2006, 00:00

  • PUK15 MODELLING COST-EFFECTIVENESS USING A DYNAMIC PRICE PATH WITH GENERIC SUBSTITUTION SCENARIOS- COSTEFFECTIVENESS OF CINACALCET IN UK PATIENTS WITH END-STAGE RENAL DISEASE (ESRD) ON HEMODIALYSIS

    Nov 1, 2006, 00:00

  • IN4 MEDICAL MANAGEMENT AND COSTS ASSOCIATED WITH STAPHYLOCOCCUS AUREUS (SA) BACTERAEMIA IN HAEMODIALYSIS PATIENTS-A COST-OF-ILLNESS STUDY

    Nov 1, 2006, 00:00

  • POS2 LOSS OF TREATMENT BENEFIT DUE TO LOW COMPLIANCE WITH BISPHOSPHONATE THERAPY

    Nov 1, 2006, 00:00

  • PCV34 A COST-EFFECTIVENESS ANALYSIS OF OLMESARTAN IN THE TREATMENT OF ARTERIAL HYPERTENSION

    Nov 1, 2006, 00:00

  • PCN40 COST EFFECTIVENESS OF RITUXIMAB PLUS CVP IN PREVIOUSLY UNTREATED INDOLENT NON-HODGKIN'S LYMPHOMA

    Nov 1, 2006, 00:00

  • PIH16 TREATMENT DURATION FOR ATROPHIC VAGINITIS- CLINICAL TRIALS VERSUS “THE REAL WORLD”

    Nov 1, 2006, 00:00

  • PDB19 COMPARATIVE OUTCOMES-BASED HEALTH ECONOMIC EVALUATION OF TYPE 2 DIABETES PATIENTS ON BASAL INSULIN ANALOGS

    Nov 1, 2006, 00:00

  • PHM12 PHYSICIANS' PREFERENCES TOWARD COAGULATION FACTOR CONCENTRATES IN THE TREATMENT OF HEMOPHILIA PATIENTS WITH INHIBITORS- A DISCRETE CHOICE EXPERIMENT

    Nov 1, 2006, 00:00

  • PGI17 DEPICTION OF GASTROESOPHAGEAL REFLUX DISEASE (GERD) PREVALENCE IN PRIMARY CARE IN GREECE

    Nov 1, 2006, 00:00

  • PEY11 MODELING THE COST AND CONSEQUENCES OF RESTOR®, A MULTIFOCAL INTRAOCULAR LENS (IOL) IN REFRACTIVE SURGERY IN FRANCE

    Nov 1, 2006, 00:00

  • MC8 THE COST-EFFECTIVENESS OF SMOKING CESSATION INTERVENTIONS-ACCOUNTING FOR MEDICAL COSTS IN LONGER LIFE EXPECTANCIES

    Nov 1, 2006, 00:00

  • PCV18 OUTCOME OF THIAZOLIDINEDIONE USE IN DISCHARGED DIABETIC PATIENTS WHO WERE HOSPITALIZED FOR HEART FAILURE

    Nov 1, 2006, 00:00

  • PCV42 IMPACT OF VENTRICULAR ARRHYTHMIAS ON HOSPITALIZATION COSTS IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION (AMI)

    Nov 1, 2006, 00:00

  • PST4 DIFFERENCES IN DISCHARGE LOCATION FOR PATIENTS WITH MULTIPLE ISCHEMIC STROKE ADMISSIONS- IMPLICATIONS FOR POST-ACUTE CARE COSTS

    Nov 1, 2006, 00:00

  • PCN33 A COST-CONSEQUENCE ANALYSIS OF DARBEPOETIN ALFA ADMINISTERED EVERY 3 WEEKS (Q3W_DA) COMPARED TO WEEKLY EPOETIN ALFA (QW_EA) OR EPOETIN BETA (QW_EB) IN PATIENTS WITH CHEMOTHERAPY-INDUCED ANEMIA (CIA)-A RETROSPECTIVE STUDY

    Nov 1, 2006, 00:00

  • PEN3 COST COMPARISON OF HUMAN GROWTH HORMONE DELIVERED VIA PEN DEVICES VERSUS VIAL/SYRINGE IN ADULT PATIENTS- A BUDGETARY IMPACT MODEL

    Nov 1, 2006, 00:00

  • PHM9 THE EVALUATION OF ECONOMIES OF SCOPE IN GENETIC SCREENING BY DNA TECHNOLOGY- A MODELING STUDY

    Nov 1, 2006, 00:00

  • PIH13 PHARMACOECONOMIC ASPECTS OF REFORMS OF PHARMACEUTICAL SECTOR- MONTENEGRO EXPERIENCE

    Nov 1, 2006, 00:00

  • PDB33 THE EFFICACY OF INSULIN GLARGINE COMPARED TO OTHER INJECTABLE THERAPIES-A META-ANALYSIS OF CLINICAL OUTCOMES IN INSULIN NAÏVE TYPE 2 DIABETES PATIENTS

    Nov 1, 2006, 00:00

  • PMC17 MONITORING OF PHARMACEUTICAL COST OF REIMBURSED MEDICINES BY COMBINING OFFICIAL PHARMACY INVOICE DATA WITH COMMERCIAL IMS SALES DATA

    Nov 1, 2006, 00:00

  • PIH12 THE DETERMINANTS OF DRUGS PRESCRIPTION FOR CHILDREN IN GENERAL PRACTICE

    Nov 1, 2006, 00:00

  • PGI3 EFFICACY OF ESOMEPRAZOL IN GASTRO-OESOPHAGEAL REFLUX DISEASE (GERD) IN A MEXICAN POPULATION

    Nov 1, 2006, 00:00

  • PMC8 ECONOMIC DECISION MODELLING- CALCULATION OF TOTAL NET MONETARY BENEFITS OF GUIDELINE IMPLEMENTATION INTO CLINICAL PRACTICE

    Nov 1, 2006, 00:00

  • POB8 THE IMPACT OF BODY WEIGHT ON UTILITY SCORES IN PATIENTS WITH TYPE 2 DIABETES

    Nov 1, 2006, 00:00

  • PUK23 IMPACT OF OVERACTIVE BLADDER ON FREQUENCY OF SEXUAL ACTIVITY AND SEXUAL SATISFACTION IN WOMEN- RESULTS FROM THE EPIC STUDY

    Nov 1, 2006, 00:00

  • PCV54 COST-EFFECTIVENESS ANALYSIS OF DIAGNOSTIC METHODS IN THE MANAGEMENT OF PATIENTS WITH SYMPTOMATIC, LOWER LIMB PERIPHERAL ARTERIAL DISEASE

    Nov 1, 2006, 00:00

  • PCV24 CARDIOVASCULAR EVENTS REDUCTION AND COSTEFFECTIVENESS OF ATORVASTATIN VERSUS PRAVASTATIN IN SPANISH POPULATION WITH ACUTE CORONARY SYNDROME (ACS)

    Nov 1, 2006, 00:00

  • PIN25 LONG TERM EFFECT OF WARD PHARMACY CONTROLLED ADMINISTRATION OF ANTIBIOTICS ON ANTIMICROBIAL TREATMENT COSTS

    Nov 1, 2006, 00:00

  • PCV4 META-ANALYSIS OF THE DIAGNOSTIC ACCURACY OF PRESSURE MEASUREMENTS IN CORONARY ARTERY DISEASE

    Nov 1, 2006, 00:00

  • PCN9 ERLOTINIB IN NON-SMALL CELL LUNG CANCER (NSCLC) IN GERMANY–A COST-SAVING SECOND-LINE TREATMENT OPTION?

    Nov 1, 2006, 00:00

  • POB1 ASSESSMENT OF THE CLINICAL RISK FACTORS FOR METABOLIC SYNDROME IN A NATIONAL PRIMARY CARE ELECTRONIC HEALTH RECORD (EHR) DATABASE

    Nov 1, 2006, 00:00

  • PRS6 CONSEQUENCES FOR DRG-IMPLEMENTATION IN GERMANY- EFFECT ON DIRECT COSTS OF IN-PATIENTS WITH COMMUNITY-ACQUIRED PNEUMONIA FROM HOSPITAL'S PERSPECTIVE

    Nov 1, 2006, 00:00

  • PHP30 ASSESSING THE ECONOMIC AND SAFETY IMPACT OF GLASS VERSUS POLYMER CONTAINERS IN A RADIOLOGY DEPARTMENT

    Nov 1, 2006, 00:00

  • PND9 COST UTILITY ANALYSIS OF LEVODOPA-CARBIDOPA VS LEVODOPA-CARBIDOPA-ENTACAPONE IN PARKINSON DISEASE IN MEXICO

    Nov 1, 2006, 00:00

  • PAA7 ANALYZING THE INFLUENCE OF SWITCHING BETWEEN DIFFERENT ASTHMA REGIMES ON MEDICATION ADHERENCE TO ASTHMA THERAPY, RESOURCE UTILIZATION AND COSTS

    Nov 1, 2006, 00:00

  • PAR1 COST-EFFECTIVENESS ANALYSIS OF ETANERCEPT VS INFLIXIMAB FOR TREATMENT OF SEVERE RHEUMATOID ARTHRITIS IN BRAZIL

    Nov 1, 2006, 00:00

  • CV6 DIFFERENCES IN PERCENTAGE LOW DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) REDUCTION AND GOAL ATTAINMENT AMONG NEWLY INITIATED USERS OF STATINS IN A REAL LIFE SETTING

    Nov 1, 2006, 00:00

  • ERRATUM

    Nov 1, 2006, 00:00

  • PRS11 THE TREATMENT OF RESPIRATORY DISEASES AND HEALTH CARE BUDGET IMPACT WITHIN SLOVAKIA

    Nov 1, 2006, 00:00

  • PST6 UTILITY LOSS AND INDIRECT COSTS AFTER STROKE IN SWEDEN

    Nov 1, 2006, 00:00

  • PMC4 PRESENTING IGNORANCE- A POSSIBILITY INTERVAL APPROACH TO DEPICT HIGH-LEVEL UNCERTAINTY DUE TO CENSORING OR NON-RESPONDENTS

    Nov 1, 2006, 00:00

  • CN2 USING PSYCHOMETRIC AND CLINIMETRIC TECHNIQUES TO SELECT ITEMS FOR USE IN A NEW INSTRUMENT TO MEASURE CANCER-RELATED FATIGUE

    Nov 1, 2006, 00:00

  • PCV8 THE EFFECTIVENESS OF ROSUVASTATIN COMPARED WITH OTHER STATINS—RESULTS FROM A ROUTINE CLINICAL PRACTICE SETTING IN THE UK

    Nov 1, 2006, 00:00

  • PAA14 PATIENT-PERCEIVED SIDE EFFECTS OF CICLESONIDE AS COMPARED TO FLUTICASONE PROPIONATE IN THE TREATMENT OF MODERATE ASTHMA USING THE INHALED CORTICOSTEROID QUESTIONNAIRE

    Nov 1, 2006, 00:00

  • PEN2 COST COMPARISON OF HUMAN GROWTH HORMONE DELIVERED VIA PEN DEVICES AND VIAL/SYRINGE IN PEDIATRIC PATIENTS-A BUDGETARY IMPACT MODEL

    Nov 1, 2006, 00:00

  • MC4 BREAKING THE SILENCE- THE EFFECTS OF EXPLICIT INSTRUCTIONS ON INCORPORATING INCOME IN TTO EXCERCISES

    Nov 1, 2006, 00:00

  • PMH10 FUNCTIONAL IMPAIRMENT OF PATIENTS WITH ATTENTIONDEFICIT/ HYPERACTIVITY DISORDER (ADHD)- AN ALTERNATIVE COST-EFFECTIVENESS ANALYSIS OF CLINICALLY PROVEN TREATMENT STRATEGIES BASED UPON THE NIMH MTA STUDY

    Nov 1, 2006, 00:00

  • PMH9 COST-EFFECTIVENESS OF CLINICALLY PROVEN TREATMENT STRATEGIES FOR ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN FIVE JURISDICTIONS

    Nov 1, 2006, 00:00

  • PHP25 EXPENDITURES ON DRUGS IN DEVELOPED EUROPEAN COUNTRIES

    Nov 1, 2006, 00:00

  • PAA15 THE CONSTRUCT VALIDITY AND TEST-RETEST RELIABILITY OF THE INHALED CORTICOSTEROID QUESTIONNAIRE (ICQ)- A PATIENT SELF-REPORTED SIDE EFFECT SCALE

    Nov 1, 2006, 00:00

  • PCV69 RETROSPECTIVE STUDY OF CLOPIDOGREL USE AMONG PATIENTS WITH ACUTE CORONARY SYNDROME (ACS) UNDERGOING CORONARY ARTERY BYPASS GRAFT

    Nov 1, 2006, 00:00

  • PCN72 A COMPARISON OF PATIENT REPORTED OUTCOMES ACROSS CURATIVE TREATMENTS OF ELDERLY PROSTATE CANCER PATIENTS

    Nov 1, 2006, 00:00

  • Abstracts Index

    Nov 1, 2006, 00:00

  • PIN16 AN OBSERVATIONAL HEALTH-ECONOMIC ANALYSIS OF THE TREATMENT OF PATIENTS WITH VORICONAZOLE IN A REAL LIFE SETTING

    Nov 1, 2006, 00:00

  • RS4 CLINICALLY IMPORTANT FACTORS CONTRIBUTING TO COSTS OF CARE DEFINED VIA ANALYSIS OF COMPREHSIVE PATIENT RECORDS

    Nov 1, 2006, 00:00

  • PUK25 LINGUISTIC VALIDATION OF THE PATIENT PERCEPTION OF BLADDER CONDITION QUESTIONNAIRE (PPBC) IN 10 LANGUAGES

    Nov 1, 2006, 00:00

  • PDB6 COST-EFFECTIVENESS OF THE ONE-TOUCH® ULTRASMART® BLOOD GLUCOSE METER COMPARED WITH A CONVENTIONAL METER FOR INSULIN-USING DIABETES PATIENTS FROM THE USA

    Nov 1, 2006, 00:00

  • PDB46 QUANTIFYING THE IMPACT OF FEAR OF HYPOGLYCAEMIA ON QUALITY OF LIFE

    Nov 1, 2006, 00:00

  • PMH12 PHARMACOECONOMIC ANALYSIS OF ANTIDEPRESSANTS IN BRAZIL

    Nov 1, 2006, 00:00

  • PMH42 QUALITY OF LIFE IN PATIENTS WITH BIPOLAR DISORDER IN 5 EUROPEAN COUNTRIES

    Nov 1, 2006, 00:00

  • ES7 DIRECT MEDICAL COSTS OF STROKE ACCORDING TO HANDICAP LEVELS AFTER 12 AND 18 MONTHS

    Nov 1, 2006, 00:00

  • PCN74 UTILITIES ASSOCIATED WITH NON-SMALL CELL LUNG CANCER (NSCLC)- A COMMUNITY STUDY

    Nov 1, 2006, 00:00

  • PHM1 COST-EFFECTIVENESS OF REGULAR CONTINUOUS PROPHYLACTIC TREATMENT IN ADULT PATIENTS WITH SEVERE HEMOPHILIA A

    Nov 1, 2006, 00:00

  • PCN63 ADVANCED CUTANEOUS MALIGNANT MELANOMA- SYSTEMATIC REVIEW OF PHARMACOECONOMIC AND QUALITY OF LIFE STUDIES

    Nov 1, 2006, 00:00

  • PMH13 COST-EFFECTIVENESS OF ESCITALOPRAM VERSUS CITALOPRAM IN OUTPATIENTS SUFFERING FROM MAJOR DEPRESSIVE DISORDER

    Nov 1, 2006, 00:00

  • PCV28 COST-EFFECTIVENESS OF INTENSIVE LIPID-LOWERING TREATMENT IN SECONDARY CARDIOVASCULAR PREVENTION IN SPAIN AND GERMANY

    Nov 1, 2006, 00:00

  • PND6 RETROSPECTIVE EVALUTION OF THE DOSES OF BOTOX AND DYSPORT IN THE MANAGEMENT OF DYSTONIA—A COST MINIMISATION ANALYSIS

    Nov 1, 2006, 00:00

  • GI1 COST OF FUNCTIONAL DYSPEPSIA-RESULTS FROM A LARGE US EMPLOYER DATABASE

    Nov 1, 2006, 00:00

  • PPN1 INTRAVENOUS PARACETAMOL IN POSTOPERATIVE PAIN MANAGEMENT–SYSTEMATIC REVIEW AND META ANALYSIS OF RANDOMIZED CONTROLLED TRIALS

    Nov 1, 2006, 00:00

  • POB2 COST-EFFECTIVENESS OF TREATING CARDIOMETABOLIC PATIENTS WITH RIMONABANT (ACOMPLIA®) IN A DANISH SETTING

    Nov 1, 2006, 00:00

  • PCV60 A CARE MAP FOR CHF IN THE UK

    Nov 1, 2006, 00:00

  • PND1 META-ANALYSIS OF THE EFFICACY AND TOLERABILITY OF PRAMIPEXOLE AND ROPINIROLE IN RESTLESS LEGS SYNDROME (RLS)

    Nov 1, 2006, 00:00

  • MC1 GROWTH, CHARACTERISTICS, AND QUALITY OF THE COSTUTILITY LITERATURE THROUGH 2003

    Nov 1, 2006, 00:00

  • PDB32 AMPUTATIONS IN DIABETIC FOOT ULCER PATIENTS USING NPWT

    Nov 1, 2006, 00:00

  • PRS4 THE COST-EFFECTIVENESS OF DRUG THERAPY IN COMMUNITY-ACQUIRED PNEUMONIA AND THE IMPACT OF ANTIMICROBIAL RESISTANCE IN GERMANY

    Nov 1, 2006, 00:00

  • PHP11 DOSE DISPENSED MEDICINE AND ASSOCIATED MEDICINE AND HEALTH CARE COST

    Nov 1, 2006, 00:00

  • PCV26 COST-EFFECTIVENESS OF CLOPIDOGREL IN MEXICO- A LONG TERM ANALYSIS

    Nov 1, 2006, 00:00

  • PHP7 A SURVEY OF UK HEALTH CARE WORKERS' VIEWS ON THE USE OF HANDHELD COMPUTERS IN EVIDENCE-BASED CLINICAL PRACTICE

    Nov 1, 2006, 00:00

  • GI4 COST-EFFECTIVENESS OF TRIPLE THERAPIES OF ESOMEPRAZOLE AND RABEPRAZOLE FOR H. PYLORI ERADICATION IN THE PUBLIC SECTOR OF HONG KONG

    Nov 1, 2006, 00:00

  • PUK14 A COST-UTILITY ANALYSIS IN A UK SETTING OF CINACALCET FOR SECONDARY HYPERPARATHYROIDISM IN END STAGE RENAL DISEASE

    Nov 1, 2006, 00:00

  • PPN2 META-ANALYSIS OF DULOXETINE VS. PREGABALIN AND GABAPENTIN IN THE TREATMENT OF PERIPHERAL DIABETIC NEUROPATHIC PAIN

    Nov 1, 2006, 00:00

  • PCV55 ECONOMIC EVALUATION OF DRUG ELUTING STENTS- COST-UTILITY ANALYSIS

    Nov 1, 2006, 00:00

  • PST5 THE WEAKNESS OF TEAMWORK BETWEEN NURSES AND PHYSIOTHERAPISTS IN CARING FOR STROKE PATIENTS IN HUNGARY

    Nov 1, 2006, 00:00

  • PMH33 STRUCTURAL EQUATION MODELLING OF SCHIZOPHRENIA EARLY RETIREMENT IN GERMANY

    Nov 1, 2006, 00:00

  • PEY4 EFFECTIVENESS OF BRIMONIDINE VERSUS BRINZOLAMIDE IN TREATMENT OF GLAUCOMA- AN ANALYSIS CONDUCTED ON THE UNITED-KINGDOM GENERAL PRACTITIONER RESEARCH DATABASE

    Nov 1, 2006, 00:00

  • PCN20 COST-EFFECTIVENESS ANALYSIS OF LETROZOLE COMPARED TO TAMOXIFEN FOR TREATMENT OF EARLY BREAST CANCER IN THE HUNGARIAN HEALTH CARE SETTING

    Nov 1, 2006, 00:00

  • PDB47 A USEFUL TOOL FOR EVALUATING THE FEAR OF INJECTING AND SELF-TESTING IN DIABETIC PATIENTS-THE SPANISH VERSION OF THE DIABETES FEAR OF INJECTING AND SELF-TESTING QUESTIONNAIRE (D-FISQ)

    Nov 1, 2006, 00:00

  • OA3 HOW DO PRESCRIBERS ACT WHEN A PRODUCT IS WITHDRAWN FROM THE MARKET? FIRST LESSONS FROM THE COX-2 INHIBITORS PATIENTS POST ROFECOXIB STUDY (CIPRES)

    Nov 1, 2006, 00:00

  • PCV76 THE GERMAN CARDIOMETABOLIC COST DATABASE—A METHODOLOGICAL APPROACH TO ASSESS COST DATA FOR MODELLING COST-EFFECTIVENESS OF TREATMENT REGIMES FOR PATIENTS WITH MULTIPLE CARDIOMETABOLIC RISK FACTORS

    Nov 1, 2006, 00:00

  • PGI19 A COMMUNITY PERSPECTIVE ON THE EFFECT OF GASTROESOPHAGEAL REFLUX DISEASE ON PRODUCTIVITY WHILE AT WORK IN FRANCE

    Nov 1, 2006, 00:00

  • PHM5 ECONOMIC ANALYSIS OF SURGICAL INTERVENTIONS IN ROMANIAN HAEMOPHILIACS

    Nov 1, 2006, 00:00

  • PRS17 VALIDATION OF THE COPD SEVERITY SCORE FOR USE IN THE SPANISH PRIMARY HEALTH CARE SYSTEM, THE NEREA STUDY- PRELIMINARY RESULTS

    Nov 1, 2006, 00:00

  • Longitudinal Metric Properties of Disability Rating Scales for Parkinson's Disease

    Nov 1, 2006, 00:00

  • PCV44 COMORBIDITIES, COSTS AND THERAPEUTIC GOALS ACHIEVED IN THE SECONDARY PREVENTION OF THE PRIMARY HEALTH CARE

    Nov 1, 2006, 00:00

  • PIH10 SERVICE UTILIZATION AND HEALTH CARE COSTS OF THE ELDERLY POPULATION IN GERMANY

    Nov 1, 2006, 00:00

  • PEY21 IMPACT OF BILATERAL NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AND RELATED VISUAL IMPAIRMENT ON PATIENTS' QUALITY OF LIFE AND FUNCTIONING- A SURVEY OF FIVE COUNTRIES

    Nov 1, 2006, 00:00

  • CV8 REAL WORLD MORTALITY OF THE HYPERTENSIVE PATIENT AS DEFINED IN THE ASCOT-LLA

    Nov 1, 2006, 00:00

  • PCN22 COST-EFFECTIVENESS (CE) OF THE PREVENTION OF ORAL MUCOSITIS (OM) WITH KEPIVANCE® (PALIFERMIN) IN PATIENTS UNDERGOING MYELOABLATIVE THERAPY WITH AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN SPAIN

    Nov 1, 2006, 00:00

  • PND7 PREDICTORS OF HEALTH CARE AND NON-HEALTH COSTS IN PATIENTS WITH REFRACTORY EPILEPSY IN SPAIN- FINDINGS FROM THE LINCE STUDY

    Nov 1, 2006, 00:00

  • PMH1 COST-EFFECTIVENESS OF CLINICALLY PROVEN TREATMENT STRATEGIES FOR ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)- IMPACT OF COEXISTING CONDITIONS

    Nov 1, 2006, 00:00

  • PCN13 COST-EFFECTIVENESS OF ADJUVANT CAPECITABINE, MAYO CLINIC AND DE GRAMONT REGIMENS FOR STAGE III COLON CANCER IN THE FRENCH SETTING

    Nov 1, 2006, 00:00

  • PEY18 CHANGES IN MEDICAL AND SURGICAL TREATMENTS OF GLAUCOMA BETWEEN 1997 AND 2003 IN FRANCE

    Nov 1, 2006, 00:00

  • PCV87 COMPARING COMPLIANCE AND PERSISTENCE RATES FOR HYPERTENSION, DYSLIPIDEMIA, AND DIABETES MEDICATIONS

    Nov 1, 2006, 00:00

  • PCN32 COST-MINIMIZATION ANALYSIS OF ORAL VS. IV FLUDARABINE FOR THE TREATMENT OF B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (B-CLL) IN BRAZIL

    Nov 1, 2006, 00:00

  • PCN48 A MODEL FOR PROJECTING BOWEL CANCER INCIDENCE AND MORTALITY- APPLICATION TO THE UK BOWEL CANCER SCREENING PROGRAM

    Nov 1, 2006, 00:00

  • POS11 EVOLUTION OF THE CONSUMPTION OF BISPHOSPHONATES AND RALOXIFENE FINANCED BY THE SPANISH NATIONAL HEALTH SYSTEM FOR OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN

    Nov 1, 2006, 00:00

  • PIH14 DETECTION OF SEMANTIC AMBIGUITY IN THE ITALIAN CHILD-FRIENDLY EQ-5D VERSION

    Nov 1, 2006, 00:00

  • PHP18 PRICES OF GENERIC DRUGS IN FINLAND VS. EUROPE

    Nov 1, 2006, 00:00

  • PMH43 IMPACT OF NEGATIVE SYMPTOMS ON FUNCTIONING OF PATIENTS WITH SCHIZOPHRENIA IN FIVE EUROPEAN COUNTRIES

    Nov 1, 2006, 00:00

  • PCV85 COMPLIANCE AND PERSISTENCE OF FIXED DOSE VERSUS FREE DOSE COMBINATION THERAPY WITH VALSARTAN AND HCTZ FOR PATIENTS WITH HYPERTENSION

    Nov 1, 2006, 00:00

  • PCV27 COST-EFFECTIVENESS OF BETALOC COMPARED TO CARVEDILOL IN CARDIAC INSUFFICIENCY AND ARTERIAL HYPERTENSION TREATMENT IN POLAND

    Nov 1, 2006, 00:00

  • PUK12 DECISION MODEL OF RESOURCE (TIME) SAVINGS GENERATED BY EXTENDED DOSING OF ERYTHROPOIESIS STIMULATING PROTEIN (ESP) FOR THE TREATMENT OF ANEMIA IN CHRONIC KIDNEY DISEASE (CKD) PATIENTS

    Nov 1, 2006, 00:00

  • PDB34 A POPULATION-BASED STUDY OF THE TIME TO INSULIN INITIATION/INTENSIFICATION AFTER FAILURE ON CURRENT THERAPY IN PATIENTS WITH TYPE 1 AND TYPE 2 DIABETES IN THE UK

    Nov 1, 2006, 00:00

  • PCV48 MEDICATION USE AND ASSOCIATED ANNUAL COSTS IN PATIENTS AT RISK OF ATHEROTHROMBOSIS- RESULTS FOR GERMANY, SPAIN AND THE UK FROM THE REDUCTION OF ATHEROTHROMBOSIS FOR CONTINUED HEALTH (REACH) REGISTRY

    Nov 1, 2006, 00:00

  • PCV1 CLINICAL IMPACT OF DIAGNOSTIC IMAGING OF LOWER EXTREMITY PERIPHERAL VASCULAR DISEASE

    Nov 1, 2006, 00:00

  • PEY3 COMPARING EFFICACY OF PROSTAGLANDIN ANALOGUES FOR CONTROLLING INTRA-OCULAR PRESSURE (IOP)- RESULTS OF A META-ANALYSIS

    Nov 1, 2006, 00:00

  • PEY6 POSTERIOR CAPSULAR OPACIFICATION AND ND- YAG LASER TREATMENT AFTER CATARACT SURGERY IN FRANCE- COMPARISON ACCORDING TO INTRAOCULAR LENS WITH SQUARE EDGED OPTIC DESIGN

    Nov 1, 2006, 00:00

  • PUK21 RESEARCH NETWORK ON TRANSPLANTATION- FEMALES ON THE WAITING LIST FOR RENAL TRANSPLANT SHOW A POORER PERCEIVED STATE OF HEALTH THAN DO MALES

    Nov 1, 2006, 00:00

  • PEN1 DETERMINATION OF THE TOTAL COST OF DIAGNOSTIC PROCEDURE BY FINE NEEDLE ASPIRATION CYTOLOGY IN PATIENTS WITH THYROID NODULES

    Nov 1, 2006, 00:00

  • PHP26 SUPPLY SIDE COST-CONTAINMENT IN GERMANY- WIN SOME, LOSE SOME

    Nov 1, 2006, 00:00

  • PIH17 ASSESSING PSYCHOLOGICAL BURDEN AND TREATMENT BENEFITS IN PEDIATRIC PATIENTS WITH BEDWETTING

    Nov 1, 2006, 00:00

  • PGI15 HEALTH-STATE UTILITIES IN LIVER DISEASE- A SYSTEMATIC REVIEW AND META-ANALYSIS

    Nov 1, 2006, 00:00

  • PCV58 THE ROLE OF ECONOMIC FACTORS IN THERAPEUTIC DECISION MAKING CONCERNING TREATMENT OF CORONARY ARTERY DISEASE IN POLAND

    Nov 1, 2006, 00:00

  • PND8 COST-EFFECTIVENESS OF TREATING RESTLESS LEGS PATIENTS WITH PRAMIPEXOLE COMPARED TO NO TREATMENT IN SWEDEN

    Nov 1, 2006, 00:00

  • PHP21 ANALYSIS OF COST OF ILLNESS IN THE NETHERLANDS IN 2003- INTEGRATING NATIONAL AND INTERNATIONAL PERSPECTIVES ON HEALTH CARE COSTS

    Nov 1, 2006, 00:00

  • PMH45 CROSS-SECTIONAL EVALUATION OF HEALTH STATE UTILITY IN SWEDISH OUTPATIENTS SUFFERING FROM MAJOR DEPRESSIVE DISORDER

    Nov 1, 2006, 00:00

  • POB6 IN EUROPE, HOW REPRESENTATIVE ARE OVERWEIGHT/OBESE SUBJECTS RECRUITED VIA THE INTERNET?

    Nov 1, 2006, 00:00

  • PST3 RESOURCE UTILIZATION AND COSTS OF STROKES IN A THIRD LEVEL HOSPITAL IN MÉXICO

    Nov 1, 2006, 00:00

  • PIN22 TREATMENT PATTERNS AND OUTCOMES ASSOCIATED WITH MULTIDRUG RESISTANT STAPHYLOCOCCUS AUREUS INFECTIONS (MRSA) IN CANADIAN TEACHING HOSPITALS- INTERIM ANALYSIS

    Nov 1, 2006, 00:00

  • PAR10 THE COST-UTILITY OF ADALIMUMAB (HUMIRA®) IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) IN DENMARK

    Nov 1, 2006, 00:00

  • PCV10 COST-EFFECTIVENESS OF A LIFESTYLE INTERVENTION FOR HYPERTENSION- AN OPEN RANDOMISED CONTROLLED TRIAL

    Nov 1, 2006, 00:00

  • POS8 THE SOCIETAL BURDEN OF OSTEOPOROSIS

    Nov 1, 2006, 00:00

  • PGI14 COMPARATIVE EFFICACY OF PARIET (RABEPRAZOLE)- LESSONS FROM CLAIMS DATA

    Nov 1, 2006, 00:00

  • PMC6 IMPLEMENTING NATURAL HISTORY STUDIES IN EURASIA- THE NIEMANN-PICK EXPERIENCE WITH RAPIDLY CHANGING NATIONAL REGULATIONS

    Nov 1, 2006, 00:00

  • ES6 ENTRY AND PRICE RESPONSE IN MARKETS WITHOUT PATENT PROTECTION-THE CASE OF PHARMACEUTICALS IN ARGENTINA

    Nov 1, 2006, 00:00

  • PAR11 ARE THEY MEASURABLE? A STUDY ON ELICITING INDIRECT AND INTANGIBLE COSTS OF KNEE OSTEOARTHRITIS USING HUMAN CAPITAL APPROACH AND WILLINGNESS-TO-PAY IN MULTIETHNIC ASIAN POPULATION IN SINGAPORE

    Nov 1, 2006, 00:00

  • PSK4 COST-EFFECTIVENESS OF TOPICAL CALCIPOTRIOL/BETAMETHASONE DIPROPIONATE TWOCOMPOUND PRODUCT IN A SCOTTISH CARE MODEL

    Nov 1, 2006, 00:00

  • POS14 QUALITY OF LIFE ACCORDING TO EQ-5D AFTER OSTEOPOROTIC HIP FRACTURE IN POLAND

    Nov 1, 2006, 00:00

  • PHP29 PHARMACEUTICAL BUDGET ALLOCATION- A CAPITATION MODEL

    Nov 1, 2006, 00:00

  • PCV56 ESTIMATION OF THE PRESENCE OF CARDIOVASCULAR EVENTS AND DIRECT COSTS ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN AN AMBULATORY SETTING

    Nov 1, 2006, 00:00

  • PCN18 A SENSITIVITY ANALYSIS OF THE COST PER QUALITY ADJUSTED LIFE YEAR (QALY) OF TRASTUZUMAB IN THE TREATMENT OF EARLY BREAST CANCER (EBC)

    Nov 1, 2006, 00:00

  • OA4 A HEALTH-ECONOMIC EVALUATION OF RHBMP-2 IN SPINE FUSION SURGERY IN GERMANY AND UK

    Nov 1, 2006, 00:00

  • PIN28 IS THE PRESCRIBING OF ANTIBIOTICS FOR THE MOST COMMON INFECTIONS IN PRIMARY HEALTH CARE RATIONAL OR NOT?

    Nov 1, 2006, 00:00

  • PIH1 BUDGET IMPACT ANALYSIS OF AVODART (DUTASTERIDE) IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) IN POLAND

    Nov 1, 2006, 00:00

  • PAR4 HEALTH CARE UTILIZATION AND COSTS ASSOCIATED WITH BLUNT AND PENETRATING TRAUMA IN A UNITED STATES MANAGED CARE POPULATION

    Nov 1, 2006, 00:00

  • PIN4 ANTIBIOTIC THERAPY OF NOSOCOMIAL INFECTION IN THE INTENSIVE CARE UNIT- A COST-EFFECTIVENESS ANALYSIS

    Nov 1, 2006, 00:00

  • PCN19 COST-EFFECTIVENESS OF CETUXIMAB IN COMBINATION WITH RADIOTHERAPY VERSUS RADIOTHERAPY ALONE IN THE TREATMENT OF LOCALLY ADVANCED HEAD AND NECK CANCER IN SPAIN

    Nov 1, 2006, 00:00

  • PCV41 A COST CONSEQUENCE ANALYSIS OF THE IMPACT OF JBS 2 ON PATIENTS ELIGIBLE FOR STATIN TREATMENT IN SCOTLAND

    Nov 1, 2006, 00:00

  • PDB9 THE ECONOMIC BENEFIT OF SELF-MONITORING OF BLOOD GLUCOSE (SMBG) IN TYPE 2 NON INSULIN TREATED DIABETES PATIENTS IN SWITZERLAND

    Nov 1, 2006, 00:00

  • PEY17 COST-EFFECTIVENESS OF PEGAPTANIB IN AGE-RELATED MACULAR DEGENERATION- IMPACT OF DIFFERENCES BETWEEN US AND UK HEALTH CARE SYSTEMS

    Nov 1, 2006, 00:00

  • PR4 PREFERENCES OF PEOPLE WITH DIABETES FOR INHALED AND INJECTABLE INSULIN REGIMENS

    Nov 1, 2006, 00:00

  • PAR6 COST-UTILITY ANALYSIS OF RITUXIMAB AS A NEW THERAPEUTIC OPTION FOR RHEUMATOID ARTHRITIS PATIENTS IN CANADA

    Nov 1, 2006, 00:00

  • PCN42 COST EFFECTIVENESS OF FULVESTRANT AS AN ADDITIONAL ENDOCRINE STEP IN THE TREATMENT SEQUENCE FOR HORMONE RESPONSIVE ADVANCED BREAST CANCER

    Nov 1, 2006, 00:00

  • PMC5 INDIRECT COSTS OF COMMON COLD IN GERMANY

    Nov 1, 2006, 00:00

  • PCV36 A HEALTH ECONOMIC EVALUATION OF CONCOMITANT SURGICAL ABLATION FOR ATRIAL FIBRILLATION

    Nov 1, 2006, 00:00

  • PHP28 PILOT STUDY OF THE IMPACT OF NEW PRICING SCHEMA ON DRUG PRICES IN REPUBLIC SERBIA

    Nov 1, 2006, 00:00

  • PIN21 COST-BENEFIT ANALYSIS OF VACCINATION PROGRAMME AGAINST POLIOMYELITIS IN MALAYSIA- ORAL POLIO VACCINE (OPV) VS INACTIVATED POLIO VACCINE (IPV)

    Nov 1, 2006, 00:00

  • PMH17 COST-EFFECTIVENESS OF LONG ACTING METHYLPHENIDATE-OROS IN ADHD YOUTHS WITH SUBOPTIMAL SYMPTOM CONTROL ON IMMEDIATE-RELEASE METHYLPHENIDATE IN THE NETHERLANDS

    Nov 1, 2006, 00:00

  • PIH9 THE ECONOMIC BURDEN OF DRUGS FOR CHILDREN CARE IN GENERAL PRACTICE- AN OBSERVATIONAL STUDY IN FRANCE

    Nov 1, 2006, 00:00

  • PCN39 COST-UTILITY ANALYSIS IN A FRENCH SETTING OF ADJUVANT THERAPY WITH HERCEPTIN IN PATIENTS WITH HER-2 POSITIVE BREAST CANCER

    Nov 1, 2006, 00:00

  • PIH25 THE COUPLE-PROJECT- POOLED ANALYSIS OF SATISFACTION WITH VARDENAFIL TREATMENT IN MEN WITH ERECTILE DYSFUNCTION AND THEIR PARTNERS

    Nov 1, 2006, 00:00

  • PEY13 LAST STAGE GLAUCOMA IN EUROPE- COSTS AND QUALITY OF LIFE OF PATIENTS FROM 4 COUNTRIES

    Nov 1, 2006, 00:00

  • POS15 CHANGES IN THE HEALTH STATUS AFTER FEMORAL NECK FRACTURE MEASURED BY EQ-5D

    Nov 1, 2006, 00:00

  • PCV78 TOWARDS A MODELLED ECONOMIC EVALUATION TO IDENTIFY THE OPTIMAL POPULATION FOR SCREENING OF CORONARY ARTERY DISEASE

    Nov 1, 2006, 00:00

  • PMH11 RATIONAL CHOICE OF TREATMENT STRATEGY IN MODERATE TO SEVERE ALZHEIMER'S DISEASE PATIENTS LIVING IN CANADA

    Nov 1, 2006, 00:00

  • PDB36 THE TRANSLATION AND LINGUISTIC VALIDATION OF THE SATISFACTION WITH ORAL ANTI-DIABETIC AGENTS (SOADA) QUESTIONNAIRE

    Nov 1, 2006, 00:00

  • PCN52 SCREENING RATE IN THE HUNGARIAN ORGANIZED NATIONWIDE CERVICAL CANCER SCREENING PROGRAMME

    Nov 1, 2006, 00:00

  • PHM6 SOCIETAL COSTS OF ALLOGENEIC BLOOD TRANSFUSION IN THE NETHERLANDS

    Nov 1, 2006, 00:00

  • PIH15 DEVELOPMENT OF AN ICIQ NOCTURNAL ENURESIS QOL QUESTIONNAIRE

    Nov 1, 2006, 00:00

  • PMH27 COST-EFFECTIVENESS OF COGNITIVE-BEHAVIOURAL THERAPY (CBT) FOR MENTAL ILLNESS- AN INTERNATIONAL REVIEW

    Nov 1, 2006, 00:00

  • PEY14 BIMATOPROST, LATANOPROST, AND TRAVOPROST FOR THE TREATMENT OF GLAUCOMA-A COST-EFFECTIVENESS ANALYSIS IN SCANDINAVIA USING A DECISION-ANALYTIC HEALTH ECONOMIC MODEL

    Nov 1, 2006, 00:00

  • PHP19 DRUG PRICE INDICES 1980–2005 IN FINLAND

    Nov 1, 2006, 00:00

  • PCV50 EFFICACY AND SOCIOECONOMIC RELEVANCE OF HAWTHORN EXTRACT (CRATAEGUS) WS® 1442 IN THE TREATMENT OF NYHA II CHF PATIENTS—RESULTS FROM A PROSPECTIVE THREE-YEAR PHARMACOECONOMIC STUDY

    Nov 1, 2006, 00:00

  • PEY12 MODELING THE COSTS AND CONSEQUENCES OF RESTOR®, A MULTIFOCAL INTRAOCULAR LENS (IOL), AFTER CATARACT SURGERY IN FRANCE

    Nov 1, 2006, 00:00

  • DB2 INSULIN THERAPY AMONG TYPE 2 DIABETES PATIENTS- IMPACT OF CONVERSION TO A PEN DEVICE ON ADHERENCE, HYPOGLYCEMIC EVENTS, AND COSTS

    Nov 1, 2006, 00:00

  • PSM2 COST-UTILITY ANALYSIS FOR SMOKING CESSATION THERAPY IN JAPAN

    Nov 1, 2006, 00:00

  • PIH7 COST-EFFECTIVENESS OF SINGLE-EMBRYO-TRANSFER (SET) VERSUS DOUBLE-EMBRYO-TRANSFER (DET) STRATEGIES IN IN-VITRO FERTILIZATION

    Nov 1, 2006, 00:00

  • PSK6 BELGIAN DRUG UTILISATION STUDY OF ELIDEL® IN ROUTINE PRACTICE IN ATOPIC DERMATITIS

    Nov 1, 2006, 00:00

  • PCN45 COST EFFECTIVENESS OF ADDING IMATINIB TO CHEMOTHERAPY IN ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ALL)-AN EXPLORATORY ANALYSIS FOR THE UK

    Nov 1, 2006, 00:00

  • PDB42 PATIENT AND PHYSICIAN DRIVERS OF HEALTH-RELATED QUALITY LIFE OF PATIENTS WITH TYPE 2 DIABETES IN PRIMARY CARE IN SPAIN

    Nov 1, 2006, 00:00

  • PRS16 MEASURING THE IMPACT OF COPD ON PATIIENTS' LIVES IN AN INTERNATIONAL STUDY

    Nov 1, 2006, 00:00

  • PGI4 ESOMEPRAZOLE VERSUS OTHER PROTON-PUMP INHIBITORS (PPI)- CLINICAL AND COST EFFECTIVENESS ANALYSIS

    Nov 1, 2006, 00:00

  • PHP20 SWITCH PATTERNS AROUND PATENT EXPIRY WITH ECONOMIC IMPLICATIONS FOR THE NETHERLANDS

    Nov 1, 2006, 00:00

  • PAA9 THE EFFECTS OF GENERIC-ONLY DRUG COVERAGE ON INHALED CORTICOSTEROID EXPENDITURES AND USE

    Nov 1, 2006, 00:00

  • PIH4 THE COST EFFECTIVENESS OF IVF IN ITALY- IMPLICATIONS OF A NEW LAW

    Nov 1, 2006, 00:00

  • PCV7 REACHING AWMSG TARGETS AND BEYOND-A RETROSPECTIVE AUDIT OF TARGETS ACHIEVED THROUGH USE OF ROSUVASTATIN IN WELSH GENERAL PRACTICE

    Nov 1, 2006, 00:00

  • PCV46 NON-HOSPITAL COSTS AND NUMBER OF CARDIOVASCULAR RISK FACTORS (CVRF) IN SPANISH HIPERTENSIVE PATIENTS

    Nov 1, 2006, 00:00

  • PRS7 ESTIMATION OF MORBIDITY, RESOURCE UTILIZATION AND COST IN SUBJECTS TREATED WITH TIOTROPIUM BROMIDE FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN A SPANISH POPULATION SETTING

    Nov 1, 2006, 00:00

  • PGI2 PROTON PUMP INHIBITORS FOR THE TREATMENT OF REFLUX OESOPHAGITIS- ENDOSCOPIC HEALING RATES FROM A SYSTEMATIC REVIEW OF RANDOMISED CONTROLLED TRIALS

    Nov 1, 2006, 00:00

  • PGI11 ECONOMIC EVALUATION OF THE PHARMACOLOGICAL THERAPY OF BLEEDING ESOPHAGEAL VARICES IN MEXICO

    Nov 1, 2006, 00:00

  • PHP16 ATTITUDES TOWARD HOME CARE AMONG ACUTELY HOSPITALIZED PATIENTS IN HUNGARY

    Nov 1, 2006, 00:00

  • PEY19 PROSTAGLANDIN AGONIST USE WITH AND WITHOUT ADJUNCTIVE THERAPY FOR THE TREATMENT OF GLAUCOMA- A CANADIAN POPULATION BASED ANALYSIS

    Nov 1, 2006, 00:00

  • PEY1 USE OF BAYESIAN NETWORKS TO SPECIFY THE NOCTURNAL INTRA-OCULAR PRESSURE PEAK FROM DAYTIME MEASUREMENTS IN GLAUCOMA PATIENTS

    Nov 1, 2006, 00:00

  • PUK16 COST-EFFECTIVENESS ANALYSIS OF SOLIFENACIN FLEXIBLE DOSING IN PATIENTS WITH OVERACTIVE BLADDER SYMPTOMS IN FOUR NORDIC COUNTRIES

    Nov 1, 2006, 00:00

  • PHM4 SYSTEMATIC REVIEW OF THE COSTS OF HEMATOLOGIC ADVERSE EVENTS IN ADULT CANCER PATIENTS TREATED WITH CHEMOTHERAPY

    Nov 1, 2006, 00:00

  • PSK5 COST OF ATOPIC DERMATIS IN ADULTS- THE CODA STUDY

    Nov 1, 2006, 00:00

  • PDB17 SELF MONITORING OF BLOOD GLUCOSE IN PATIENTS WITH TYPE 2 DIABETES- COST UTILITY ANALYSIS IN A GERMAN GOVENMENT PAYER SETTING

    Nov 1, 2006, 00:00

  • HP2 TRENDS IN ANGIOTENSIN II RECEPTOR BLOCKER (ARB) PRESCRIBING AMONG GENERAL PRACTITIONERS IN THE UK

    Nov 1, 2006, 00:00

  • PIN2 A COST-BENEFIT ANALYSIS OF DIFFERENT VARICELLA VACCINATION STRATEGIES INVOLVING ITALIAN CHILDREN AND ADOLESCENTS

    Nov 1, 2006, 00:00

  • GI2 DICLOFENAC-ASSOCIATED ULCER RISK IS REDUCED BY PROTON PUMP INHIBITORS- NESTED CASE CONTROL STUDY

    Nov 1, 2006, 00:00

  • PEY26 VISION BENEFIT FROM MULTI-FOCAL INTRAOCULAR LENS (IOL) AFTER CATARACT SURGERY ESTIMATED BY PRINCIPAL COMPONENTS ANALYSIS

    Nov 1, 2006, 00:00

  • DB3 GLYCEMIC RESPONSE TO NEWLY INITIATED ANTIHYPERGLYCEMIC THERAPIES IN A LARGE MANAGED CARE ORGANIZATION

    Nov 1, 2006, 00:00

  • PIN14 ECONOMIC EVALUATION OF CASPOFUNGIN (CANCIDAS®) VERSUS LIPOSOMAL AMPHOTERICIN B FOR EMPIRICAL THERAPY OF SUSPECTED SYSTEMIC FUNGAL INFECTION IN THE GERMAN HOSPITAL SETTING

    Nov 1, 2006, 00:00

  • CN4 COST-EFFECTIVENESS OF ERLOTINIB COMPARED WITH DOCETAXEL FOR THE TREATMENT OF RELAPSED NONSMALL CELL LUNG CANCER (NSCLC) IN THE UK

    Nov 1, 2006, 00:00

  • PEY9 ASSESSMENT OF THE COST-EFFECTIVENESS OF TRAVOPROST VERSUS LATANOPROST, AS SINGLE AGENTS FOR GLAUCOMA TREATMENT IN FRANCE

    Nov 1, 2006, 00:00

  • PUK8 COST-EFFICACY OF FINASTERIDE, DOXAZOSIN AND THE COMBINATION OF BOTH IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) IN FRANCE BASED ON THE MTOPS STUDY

    Nov 1, 2006, 00:00

  • PMH7 OFF-LABEL UTILIZATION OF METHYLPHENIDATE FOR ADULTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN GERMANY- INSIGHTS FROM THE NORDBADEN PROJECT

    Nov 1, 2006, 00:00

  • PCN68 QUALITY OF LIFE OF PATIENTS RECEIVING ADJUVANT CHEMOTHERAPIES FOR BREAST CANCER IN JAPAN

    Nov 1, 2006, 00:00

  • PDB24 COST OF A MAJOR HYPOGLYCAEMIC EVENT IN TYPE 1 AND TYPE 2 DIABETIC PATIENTS-A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2006, 00:00

  • PCV84 COMPLIANCE IMPROVEMENTS AND HDL CHOLESTEROL LEVELS IN HYPERTENSIVE PATIENTS IN SPAIN

    Nov 1, 2006, 00:00

  • PCN41 COST-EFFECTIVENESS OF TAC VERSUS FAC FOR THE TREATMENT OF NODE POSITIVE BREAST CANCER IN THE ADJUVANT SETTING

    Nov 1, 2006, 00:00

  • HP1 CRITICAL APPRAISAL OF ECONOMIC EVALUATIONS OF CHOLESTEROL LOWERING DRUGS-A SYSTEMATIC REVIEW

    Nov 1, 2006, 00:00

  • PCN24 PEGFILGRASTIM PRIMARY PROPHYLAXIS IS MORE COSTEFFECTIVE THAN FILGRASTIM IN WOMEN WITH BREAST CANCER RECEIVING CHEMOTHERAPY IN FRANCE

    Nov 1, 2006, 00:00

  • PMC15 HOSPITAL PHARMACY DRUG DELIVERY TIME- A WORK FLOW MANAGEMENT ISSUE

    Nov 1, 2006, 00:00

  • Integrating the Patient's Perspective into Device Evaluation Trials

    Nov 1, 2006, 00:00

  • PIN30 PSYCHOMETRIC VALIDATION OF THE ACTIVITY IMPAIRMENT ASSESSMENT (AIA) QUESTIONNAIRE IN PATIENTS WITH ACUTE BACTERIAL SINUSITIS

    Nov 1, 2006, 00:00

  • PDB50 MYTHS AND REALITIES OF TREATMENT SATISFACTION IN DIABETES

    Nov 1, 2006, 00:00

  • POS10 OSTEOPOROSIS RELATED HEALTH CARE UTILISATION IN HUNGARY BY THE NATIONWIDE HEALTH INSURANCE DATABASE

    Nov 1, 2006, 00:00

  • PCV23 ECONOMIC BURDEN OF CONTRAST-INDUCEDNEPHROPATHY (CIN)- IMPLICATIONS FOR PREVENTION STRATEGIES

    Nov 1, 2006, 00:00

  • PCV17 PROJECTED IMPACT ON CORONARY HEART DISEASE OF ADDING PROLONGED-RELEASE NICOTINIC ACID (NIASPAN®) TO STATIN TREATMENT IN EUROPEAN PATIENTS WITH TYPE 2 DIABETES

    Nov 1, 2006, 00:00

  • PCV62 DRUG USE EVALUATION OF ROSUVASTATIN IN A HONG KONG PUBLIC HOSPITAL

    Nov 1, 2006, 00:00

  • PGI7 COST-EFFECTIVENESS OF A POTENTIAL FUTURE HELICOBACTER PYLORI VACCINE IN THE NETHERLANDS

    Nov 1, 2006, 00:00

  • PDB14 DIRECT COST FOR CONTROL OF DM IN A RURAL AREAS

    Nov 1, 2006, 00:00

  • PHP6 ESTIMATION AND COMPARISON OF OSTOMY APPLIANCE COSTS WITH REIMBURSEMENT TARIFFS IN BELGIUM

    Nov 1, 2006, 00:00

  • PMC2 EFFICIENT DATA MINING AND PROBABILISTIC INFERENCE WITH P-COURSE- A BAYESIAN METHOD WITH MULTILEVEL PRIORS FOR MEDICAL APPLICATIONS

    Nov 1, 2006, 00:00

  • PCN59 THE ECONOMIC VALUE OF INNOVATIVE TREATMENTS OVER THE PRODUCT LIFE CYCLE- THE CASE OF TRASTUZUMAB

    Nov 1, 2006, 00:00

  • PHP36 PHARMACOEPIDEMIOLOGICAL ANALYSIS OF THE USEING DRUGS FROM REIMBESMENT LIST IN RUSSIA

    Nov 1, 2006, 00:00

  • PAA5 ECONOMIC EVALUATION OF A NEW AIRWAY INFLAMMATION MONITOR IN THE DIAGNOSIS AND MANAGEMENT OF ASTHMA IN GERMANY

    Nov 1, 2006, 00:00

  • IN2 EUROPEAN SURVEILLANCE OF ANTIMICROBIAL CONSUMPTION (ESAC)- DEVELOPING VALID ANTIBIOTIC PRESCRIBING QUALITY INDICATORS FOR AMBULATORY CARE

    Nov 1, 2006, 00:00

  • PRS2 EFFECT OF DRG IMPLEMENTATION IN GERMANY–ANALYSIS OF LENGTH OF HOSPITAL STAY OF IN-PATIENTS SUFFERING FROM COMMUNITY-ACQUIRED PNEUMONIA

    Nov 1, 2006, 00:00

  • PCN73 VARIATIONS IN SATISFACTION WITH CARE AND EMOTIONAL WELL-BEING OF EARLY-STAGE PROSTATE CANCER PATIENTS

    Nov 1, 2006, 00:00

  • PMH24 ASSESSMENT OF RESOURCE UTILISATION IN ADULTS DIAGNOSED WITH DEPRESSION IN THE UK-A GPRD-BASED STUDY

    Nov 1, 2006, 00:00

  • PMH44 TRAJECTORIES OF PATIENT AND CLINICIAN REPORTED ANTIPSYCHOTIC COMPLIANCE IN THE SOHO STUDY AND THEIR CAUSES AND CONSEQUENCES

    Nov 1, 2006, 00:00

  • PCN71 PSYCHOMETRIC EVALUATION OF A PATIENT REPORTED OUTCOME QUESTIONNAIRE FOR METASTATIC COLORECTAL CANCER

    Nov 1, 2006, 00:00

  • PCN57 TRASTUZUMAB USE FOR METASTATIC BREAST CANCER–IS “MEDIAN TIME TO TREATMENT FAILURE” AN ACCURATE PARAMETER FOR BUDGET IMPACT ANALYSIS?

    Nov 1, 2006, 00:00

  • PIH3 VACCINATION WITH RIX4414 IS COST-EFFECTIVE IN A BELGIAN SETTING

    Nov 1, 2006, 00:00

  • PDB31 REIMBURSEMENT OF PHARMACEUTICALS AND BRANDGENERIC DRUG UTILIZATION- EVIDENCE FROM ORAL HYPOGLYCEMIC AGENTS FOR AMBULATORY CARE IN TAIWAN

    Nov 1, 2006, 00:00

  • PCV89 THE RELATIONSHIP BETWEEN PATIENT BELIEFS AND ADHERENCE TO CHOLESTEROL-LOWERING MEDICATIONS- IMPLICATIONS FOR DISEASE MANAGEMENT PROGRAMS

    Nov 1, 2006, 00:00

  • PDB27 A COST-UTILITY ANALYSIS OF ORLISTAT (XENICAL®) IN THE TREATMENT OF DIABETIC PATIENTS WITH MORBID OBESITY AND ADDITIONAL CVD RISK IN NORWAY

    Nov 1, 2006, 00:00

  • PCN11 PHARMACOECONOMIC ANALYSES OF ERLOTINIB COMPARED WITH BEST SUPPORTIVE CARE (BSC) FOR THE TREATMENT OF RELAPSED NON-SMALL CELL LUNG CANCER (NSCLC) FROM THE CANADIAN PUBLIC HEALTH CARE PERSPECTIVE

    Nov 1, 2006, 00:00

  • RS1 CAN PHARMACEUTICAL INDUSTRY USE REPS TO PROVIDE MEDICAL PRACTICE GUIDELINES? (MIGRAINE AND ASTHMA)

    Nov 1, 2006, 00:00

  • PUK1 FACTORS ASSOCIATED WITH OVERACTIVE BLADDER IN MEN AND WOMEN- RESULTS FROM THE EPIC STUDY

    Nov 1, 2006, 00:00

  • PCN46 EPOIETIN ALPHA TREATMENT FOR CANCER PATIENTS WITH CHEMOTHERAPY INDUCED ANAEMIA–A COSTEFFECTIVENESS ANALYSIS FOR SWEDEN

    Nov 1, 2006, 00:00

  • PDB20 THERAPY CLASS CONVERSION IN PATIENTS WITH TYPE 2 DIABETES- ECONOMIC EVALUATION OF INSULIN DETEMIR AND NPH

    Nov 1, 2006, 00:00

  • PAR5 MODELING THE ECONOMIC AND HEALTH CONSEQUENCES OF MANAGING CHRONIC OSTEOARTHRITIS PAIN WITH ORAL OPIOIDS IN GERMANY

    Nov 1, 2006, 00:00

  • PHP13 BENEFIT INCIDENCE ANALYSIS BEFORE AND AFTER UNIVERSAL COVERAGE IN THAILAND

    Nov 1, 2006, 00:00

  • PMC7 THE IMPLICATIONS OF DIFFERING ASSUMPTIONS REGARDING THE BASIS OF PLACEBO RESPONSES ON THE ESTIMATION OF COST-EFFECTIVENESS

    Nov 1, 2006, 00:00

  • PUK5 COSTS AND COST-EFFECTIVENESS OF EPOETIN IN PATIENTS WITH CHRONIC RENAL INSUFFICIENCY DURING THE PREDIALYSIS PERIOD IN POLAND

    Nov 1, 2006, 00:00

  • PAA4 PHARMACOECONOMIC ANALYSIS OF USE OF A SIMBICORT TURBUHALER AND SERETIDE MULTIDISK OF ASTHMA PATIENTS

    Nov 1, 2006, 00:00

  • PIN5 THE COST EFFECTIVENESS ANALYSIS OF TREATMENT WITH PEGINTERFERON ALFA-2A (40KD) IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B

    Nov 1, 2006, 00:00

  • PAA13 OBTAINING POPULATION REFERENCE VALUES FOR THE ESPRINT-15 QUESTIONNAIRE, A SPECIFIC QUALITY OF LIFE SCALE FOR ALLERGIC RHINITIS (AR)

    Nov 1, 2006, 00:00

  • PAR9 CO-PRESCRIPTION OF GASTROPROTECTIVE AGENTS FOR PATIENTS AT RISK OF NSNSAID-INDUCED GASTROINTESTINAL HARM

    Nov 1, 2006, 00:00

  • PEN4 EVALUATION OF THE ASSOCIATION BETWEEN THE QUALITY OF LIFE, SOCIAL CLASS AND HEIGHT IN THE GENERAL ADULT UK POPULATION

    Nov 1, 2006, 00:00

  • PCN28 SHOULD FOTEMUSTINE BE USED AS THE FIRST LINE TREATMENT

    Nov 1, 2006, 00:00

  • PHP1 DESTINATION- FOREIGN PROVIDER (MEDICAL TOURISM FOR THE GERMAN PATIENT)

    Nov 1, 2006, 00:00

  • PHP23 TIME SERIES ANALYSIS OF PHARMACEUTICAL PUBLIC EXPENDITURE- EVALUATION OF SUPPLY MEASURES

    Nov 1, 2006, 00:00

  • PIN6 PRIMARY PROPHYLAXIS AGAINST FEBRILE NEUTROPENIA WITH PEGFILGRASTIM IS MORE COST-EFFECTIVE THAN FILGRASTIM IN WOMEN WITH BREAST CANCER RECEIVING CHEMOTHERAPY IN GERMANY

    Nov 1, 2006, 00:00

  • IH2 HEALTH OUTCOMES FOR MOTHERS OF DISABLED AND CHRONICALLY ILL CHILDREN

    Nov 1, 2006, 00:00

  • PR1 HEALTH RELATED QUALITY OF LIFE IN DIFFERENT STATES OF BREAST CANCER

    Nov 1, 2006, 00:00

  • PMH3 PREVALENCE AND COMORBIDITY BURDEN IN PATIENTS WITH BIPOLAR DISORDERS- CROSS-SECTIONAL ANALYSIS OF A HEALTH-PROVIDER ADMINISTRATIVE CLAIM DATABASE

    Nov 1, 2006, 00:00

  • PCV2 CARDIOVASCULAR RISK FACTORS IN ACUTE CORONARY SYNDROME PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION IN FIVE EUROPEAN COUNTRIES

    Nov 1, 2006, 00:00
  • «
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157 (current)
  • 158
  • 159
  • 160
  • »